

Infeções Nosocomiais. COVID-19: Amigo ou Inimigo?

Nosocomial Infections. COVID-19: A Friend or Foe?

Bonito Moreira, Laura^{1*} (<https://orcid.org/0000-0002-3325-2998>); Martins-dos-Santos, Gonçalo^{2*} (<https://orcid.org/0000-0002-5726-5486>); Ilharco, Marta¹ (<https://orcid.org/0000-0002-4931-5260>); Mello Vieira, Marta¹ (<https://orcid.org/0000-0002-0030-662X>); Midões, Carolina¹ (<https://orcid.org/0000-0003-1960-5838>); Rocha, Inês³ (<https://orcid.org/0000-0002-3614-4482>); Soares, Leonor¹ (<https://orcid.org/0000-0002-3035-7700>); Fevereiro, Maria do Carmo¹ (<https://orcid.org/0000-0001-5618-7319>).

*Joint first authors

Resumo:

Introdução: As infeções nosocomiais constituem um problema de saúde pública e trazem custos excessivos evitáveis associados aos internamentos hospitalares. Durante a pandemia da COVID-19, houve uma mudança nas políticas com foco em programas de prevenção e controlo de infeção.

Métodos: Postulamos que tal mudança pode ter um efeito indireto na ocorrência de Infeções nosocomiais. Realizámos um estudo retrospectivo com o objetivo de comparar as diferenças na prevalência de infeção hospitalar entre um período COVID-19 e um período não COVID-19, numa enfermaria de Medicina Interna de um hospital central de Lisboa, sem doentes com COVID-19. Foram incluídos 393 pacientes, sendo 192 do período não COVID-19 e 201 do período COVID-19.

Resultados: Encontramos uma redução estatisticamente significativa na ocorrência de infeções nosocomiais no período COVID-19 de 16,1% (n = 31) para 5,5% (n = 11) (p = 0,001; OR 0,301; IC 95%: 0,146-0,617). Também encontramos uma redução estatisticamente significativa no uso de antibióticos (n = 31; 16,1% vs n = 11; 5,5%; p = 0,001) e na ocorrência de infeção por organismos multirresistentes (n = 9; 29,0% vs n = 1; 9,1%; p = 0,009) no período COVID-19.

Conclusão: Estes resultados confirmam que, após a implementação de protocolos sistemáticos de controlo de infeção, houve uma redução nas infeções nosocomiais. Sugerimos uma investigação mais aprofundada para validar os dados obtidos e uma análise custo-benefício para esclarecer se a implementação universal das medidas de prevenção e controlo de infeção constituirão uma mais-valia para o tratamento dos doentes.

Palavras-chave: Controlo de Infeções; COVID-19; Infeção Hospitalar/prevenção e controlo.

Abstract:

¹Department of Internal Medicine 1.4, Centro Hospitalar Universitário de Lisboa Central, Hospital de São José, Lisbon, Portugal;

²Department of Immunoallergology, Centro Hospitalar Universitário de Lisboa Central, Hospital de Dona Estefânia, Lisbon, Portugal;

³Department of Hematology, Centro Hospitalar Universitário de Lisboa Central, Hospital de Santo António dos Capuchos, Lisbon, Portugal.

Introduction: Nosocomial Infections constitute a public health problem and bring excess avoidable costs associated with hospital admissions. Over the COVID-19 pandemics there was a shift in policies focusing on infection prevention and control programs.

Methods: We postulate that such shift may have an indirect effect in the occurrence of nosocomial infections. We performed a retrospective study aiming to compare the differences in nosocomial infection prevalence between a COVID-19 period and a non-COVID-19 period, in a free-COVID-19 Internal Medicine ward from a central hospital in Lisbon. We included 393 patients, 192 patients being from the non-COVID-19 period and 201 patients from the COVID-19 period.

Results: We found a statistically significant reduction in the occurrence of nosocomial infections in the COVID-19 period from 16.1% (n = 31) to 5.5% (n = 11) (p = 0.001; OR 0.301; 95% CI: 0.146-0.617). We also found a statistically significant reduction in antibiotic usage (n = 31; 16.1% vs n = 11; 5.5%; p = 0.001) and in the occurrence of multidrug resistant organism infection (n = 9; 29.0% vs n = 1; 9.1%; p = 0.009) in the COVID-19 period.

Conclusion: Our results confirm that after implementation of systematic infection control protocols there was a reduction in nosocomial infections. We suggest further investigation to validate the data obtained and a cost-benefit analysis to clarify whether the universal implementation of infection prevention and control measures will add value to the treatment of patients.

Keywords: COVID-19; Cross Infection/prevention & control; Infection Control.

Introduction

Nosocomial infections (NI) pose a major healthcare problem with preventable associated costs. As stated by the Centres for Disease Control and Prevention (CDC), NI are a localized or systemic condition resulting from exposure to an infectious agent, at least after 48 hours of hospital admission.¹ NI are associated with an increase in complications, morbidity and mortality, and an excess cost, either by direct burden of length of stay or by loss of active days.² As of

2015, World Health Organization (WHO) has considered it a major public health problem.³ Like many adverse events, NI are potentially preventable. Efforts towards its reduction have been made by implementing local and global infection prevention and control (IPC) protocols and programs aiming to reduce NI and its costs. Best practice manuals encompass measures toward

- 1) better hand hygiene and respiratory/cough etiquette;
- 2) equipment and surface sterilization;
- 3) screening of carriers or individuals with NI risk factors;
- 4) isolation of infected individuals, usage of personal protection equipment, and creation of local commissions for outbreaks management,
- 5) proper residue and clothing handling.⁴

In the turn of 2019, a series of atypical pneumonia was identified in the Wuhan province of China. Viral genome sequencing was performed, and a new coronavirus (SARS-CoV-2) was identified in bronchoalveolar lavage fluid and bronchoalveolar epithelial cultures.⁵ Human-to-human transmission was confirmed, and it is now known that it occurs either by means of contact with droplets, coming from coughing or sneezing, faeces or by direct contact.⁶ Given the absence of specific direct treatment or vaccine, soon there was the need for stopping the chain of transmission by means of hand washing, generalized mask use, and social distancing. Health care professionals present an important vector of transmission and, given that asymptomatic individuals can still transmit the SARS-CoV-2, generalized preventive measures were instituted in all health care facilities.^{7,8}

In Portugal, the first 2 cases of coronavirus disease 2019 (COVID-19) were identified on March 2nd, 2020. Since then, in health care facilities, mask usage became mandatory and health-care professionals took measures toward minimizing the risk of transmission, such as enforcing hand hygiene policies, surface and environment cleaning, as well as assuring that minimum bed distancing was accomplished.

We aim to compare the benefits of systematic implementation of infection prevention and control measures, an indirect effect of COVID-19 pandemic, on the incidence of NI in patients admitted to a non-COVID-19 medical ward.

Methods

STUDY DESIGN AND PATIENT SELECTION

We performed a retrospective study analysis of all patients admitted in a non-COVID-19 Internal Medicine ward, in a central hospital in Lisbon, Portugal (Centro Hospitalar Universitário de Lisboa Central), comparing the incidence of NI between a non-COVID-19 period (March-May 2019) and a COVID-19 period (March-May 2020).

We admitted March 2020 as the beginning of the COVID-19 period since it represents a time when the additional infection prevention and control transmission measures had

already been implemented in our ward.

Infections were considered as nosocomial when occurred more than 48 hours after admission in the Internal Medicine ward. This assumption is possible since the time between hospital admission and ward admission can be considered irrelevant and equivalent between both periods (emergency room average length of stay was 0.7 days in the non-COVID-19 period and 0.4 days in the COVID-19 period).

Data was collected by assessment of the electronic medical records. No patients were excluded.

MEASURES IMPLEMENTED

The infection prevention and control measures implemented were

- 1) The infection control committee promoted educational and training workshops about infection protective measures;
- 2) all environmental surfaces of our ward were consistently cleaned and disinfected with alcoholic or hypochlorite solution. The target surfaces were bedside tables, beds, desks and chairs, computer keyboards, computer mice, and telephones. Besides, all door handles, floor, and toilets of our ward were cleaned and disinfected regularly;
- 3) all healthcare professionals took additional protective precautions at every interaction with the patients, through reinforcement of the already implemented hand hygiene protocols (before and after every contact with the patients or the patients' environment) and implementation of droplet (P1 face mask wearing) and contact precautions (disposable nitrile or latex gloves and disposable gowns);
- 4) all medical equipment were properly disinfected after each utilization (stethoscope, blood pressure cuff, oximeter, or electronic thermometer);
- 5) all patients and healthcare professionals wore a P1 face mask while standing on the ward;
- 6) all healthcare professionals wore exclusive hospital uniforms;
- 7) routine patient visits have been suspended. Although there was no formal evaluation of its rate of compliance, there was a permanent link between the health care professionals and the hospital infection commission, with strong awareness of the importance of the implemented measures, and all professionals took them in their daily routine.

DEFINITIONS

We considered nosocomial infection, using the CDC definition, as an infection occurring more than 48 hours after hospital admission. Hospital admission was considered as the moment in which patients were admitted in our Internal Medicine ward, since we could not guarantee that the implemented protective measures were the same in the other

wards or in the emergency department and so, it would create a risk of bias in our results.

The presence of infection was considered in the presence of clinical deterioration, organ-specific signs and symptoms, elevation of inflammatory markers with or without microorganism isolation, resulting in the prescription of an antibiotic.

Multidrug resistant (MDR) microorganisms were defined as having non-susceptibility to at least one antimicrobial drug in three or more antimicrobial categories.

Chronic kidney disease was considered for glomerular filtration rates < 60 mL/min (stage 3-5).

Immunosuppressive drug therapy was considered when taken daily, by oral or intravenous route.

STATISTICAL ANALYSIS

The statistical analysis was performed with IBM® SPSS® Statistics version 26 for Windows. The normal distribution of continuous variables was tested using the Shapiro-Wilk test and by visual analysis of the histogram. The continuous variables with non-parametric distribution assessed are represented using median and interquartile range (IQR). A comparison between the categorical variables was made using the chi-squared test or the Fisher's exact test as appropriate. A

comparison between a categorical variable and a continuous variable with non-parametric distribution was made using the Mann-Whitney U test. All statistical tests were bilateral and with a 5% significance level. Binary logistic regression models with a 95% confidence interval were used to study effects of different variables on pretended outcomes (occurrence of nosocomial infection). The measures of association relative risk reduction (RRR) and number needed to treat (NNT) were used to assess the effect of the infection control measures in the nosocomial infections.

RESULTS

CHARACTERIZATION OF POPULATION

We analysed 393 patients, 192 patients being from the non-COVID-19 period and 201 patients from the COVID-19 period. The baseline characteristics are represented in table 1.

NOSOCOMIAL INFECTIONS

From the 393 included patients, 10.7% (n = 42) developed a nosocomial infection. In the non-COVID-19 period, 31 patients (16.1%) had a nosocomial infection comparing with 11 patients (5.5%) in the COVID-19 period. These data showed a statistically significant reduction ($p = 0.001$; OR

Table 1: Baseline characteristics of patients included in both non-COVID-19 and COVID-19 periods.

Characteristic/risk factor	Non-COVID-19 period	COVID-19 period	p value*
Age, median (IQR)	78.5 (66.0-86.0)	79.0 (70.0-86.5)	0.500
Days of hospitalization, median (IQR)	9.0 (5.0-15.0)	8.0 (5.5-13.0)	0.715
Gender Female, n (%) Male, n (%)	104 (54.2%), 88 (45.8%)	106 (52.7%), 95 (47.3%)	0.776
Type 2 diabetes mellitus, n (%)	58 (30.2%)	74 (36.8%)	0.166
Chronic kidney disease, n (%)	38 (19.8%)	48 (23.9%)	0.327
Hemodialysis, n (%)	20 (10.4%)	26 (12.9%)	0.438
Chronic liver disease, n (%)	38 (19.8%)	48 (23.9%)	0.327
Alcohol abuse, n (%)	15 (7.8%)	10 (5.0%)	0.249
Rheumatic diseases, n (%)	13 (6.8%)	6 (3.0%)	0.080
Solid neoplasm, n (%)	25 (13.0%)	40 (19.9%)	0.067
Hematologic neoplasm, n (%)	3 (1.6%)	4 (2.0%)	0.749
HIV, n (%)	9 (4.7%)	13 (6.5%)	0.443
Immunosuppressive therapy, n (%)	16 (8.3%)	15 (7.5%)	0.749
Central venous catheter, n (%)	5 (2.6%)	16 (8.0%)	0.018
Urinary catheterization, n (%)	61 (31.8%)	69 (34.3%)	0.590
Total of patients, n (%)	192 (48.9%)	201 (51.1%)	

HIV - human immunodeficiency virus. IQR - interquartile range; * level of significance <0.05

Table 2: Types of nosocomial infection comparison between the non-COVID-19 and COVID-19 periods.

Type of nosocomial infection	Non-COVID-19 period (n=192) n (%)	COVID-19 period (n=201) n (%)	p value*
Urinary tract	15 (7.8%)	8 (4.0%)	0.106
Respiratory tract	12 (6.3%)	2 (1.0%)	0.005
Blood	2 (1.0%)	0 (0.0%)	0.238
Gastrointestinal tract	1 (0.5%)	0 (0.0%)	0.489
Skin and soft tissues	1 (0.5%)	1 (0.5%)	1.000
Total	31 (16.1%)	11 (5.5%)	

* level of significance <0.05

0.301; 95% CI: 0.146-0.617). The infection control measures implemented were associated with a nosocomial infection RRR of 0.66 and a NNT of 9.

The types of nosocomial infection that occurred in our population are registered in Table 2. The most common were urinary (n = 23, 5.9%) and respiratory (n = 14, 3.6%) tract infections. Comparing the two periods, we obtained an absolute and relative reduction in urinary, respiratory, blood, and gastrointestinal tract infections. However, only nosocomial respiratory tract infections had a statistically significant reduction (n = 12; 6.3% vs n = 2; 1.0%; p = 0.005),

The description of the agents implicated in NI and its classification as MDR microorganisms are represented in table 3. The most common isolated agents in the non-COVID-19 period were *Escherichia coli* (n = 7; 22.6%) and *Klebsiella pneumoniae* ESBL (n = 4; 12.9%), while *Escherichia coli* (n = 3; 27.3%) and *Pseudomonas aeruginosa* (n = 2; 18.2%) were the more frequent ones in the COVID-19 period. We found a statistically significant reduction on the incidence of MDR agents between the non-COVID-19 and the COVID-19 periods (n = 9; 29.0% vs n = 1; 9.1%; p = 0.009). The additional protective measures implemented lead to a RRR of MDR infections of 0.89 and a NNT of 24.

Table 3: Agents involved in nosocomial infections in the non-COVID-19 and COVID-19 periods.

Agent	Non-COVID-19 period Total n (%)	Non-COVID-19 period MDR n (%)	COVID-19 period Total n (%)	COVID-19 period MDR n (%)	Total n (%)
Not isolated	11 (35.5%)	-	3 (27.3%)	0 (0.0%)	14 (33.3%)
<i>Escherichia coli</i>	7 (22.6%)	2 (22.2%)	3 (27.3%)	0 (0.0%)	10 (23.4%)
<i>Escherichia coli</i> ESBL	1 (3.2%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (2.4%)
<i>Enterobacter cloacae</i>	1 (3.2%)	1 (11.1%)	1 (9.1%)	0 (0.0%)	2 (4.8%)
<i>Enterococcus faecalis</i>	2 (6.5%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	3 (7.1%)
<i>Klebsiella pneumoniae</i>	0 (0.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	1 (2.4%)
<i>Klebsiella pneumoniae</i> ESBL	4 (12.9%)	3 (33.3%)	0 (0.0%)	0 (0.0%)	4 (9.5%)
MRSA	2 (6.5%)	2 (22.2%)	0 (0.0%)	0 (0.0%)	2 (4.8%)
MSSA	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.4%)
<i>Proteus mirabilis</i>	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.4%)
<i>Pseudomonas aeruginosa</i>	0 (0.0%)	0 (0.0%)	2 (18.2%)	1 (100%)	2 (4.8%)
<i>Candida albicans</i>	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.4%)
Total	31 (100%)	9 (100%)	11 (100%)	1 (100%)	42 (100%)

ESBL - extended-spectrum beta-lactamases; MDR - multidrug resistance; MRSA - methicillin-resistant *Staphylococcus aureus*; MSSA - methicillin-susceptible *Staphylococcus aureus*;

The detailed description of the prescribed drugs to treat NI is showed in Table 4. In the non-COVID-19 period, 31 patients (16.1%) were started on antibiotics for a nosocomial infection. The most used were piperacillin-tazobactam (n = 7; 22.6%) and amoxicillin/clavulanic acid (n = 4; 12.9%) and ceftriaxone (n = 4; 12.9%). In the COVID-19 period, 11 patients (5.5%) with NI were treated with antibiotics. The used drugs were similar to the ones used in the non-COVID-19 period, although with a less absolute frequency. As all NI were treated with antibiotics, the overall use of antibiotics was statistically significant lower in the COVID-19 period compared to the non-COVID-19 period ($p = 0.001$).

From the 192 patients admitted in our ward in the non-COVID-19 period, 15 patients (7.8%) died. In the COVID-19 period (n = 201), death occurred in 32 patients (15.9%). The number of deaths by all causes occurred in the COVID-19 period was statistically significantly higher than in the non-COVID-19 period ($p = 0.013$).

ADVERSE EFFECTS OF NOSOCOMIAL INFECTIONS

Patients with a nosocomial infection admitted in our ward on both periods had a median length of hospitalization of 21.0 (12.75-27.25) days, compared to 8.0 (5.0-12.0) days in those without a nosocomial infection. In both time periods, NI were statistically significant associated with a longer length of hospitalization ($p < 0.001$).

Considering both studied periods (n = 393), 33.1% of patients (n = 130) underwent urinary catheterization. Nosocomial urinary tract infection was diagnosed in 5.9% (n = 23) and among these patients, urinary catheterization was performed in 60.9% (n = 14). Urinary catheterization, independently of the period considered, had a statistically significant association with nosocomial urinary tract infection ($p = 0.004$; OR 3.406; 95% CI: 1.433-8.095).

Although central venous catheter placement was more frequent in the COVID-19 period (n = 16 vs n=5), the frequency of NI associated with its use was the same in both periods (n = 1), with no significance difference ($p=1.000$).

In both time periods, 14.3% (n = 6) patients with a fatal outcome had a nosocomial infection. However, there was no statistically significant association between having a nosocomial infection and death ($p = 0.802$).

Discussion

The overall NI prevalence comes in line with published data, being known that it ranges from 2.5% to 15%, regardless the type of ward or level of care considered.⁹⁻¹² Specific Internal Medicine prevalence data are scarce and direct comparisons cannot be made.

Our results show a decrease in the incidence of NI after systematic implementation of IPC protocols, from 16.1% in the non-COVID-19 period to 5.5% in the COVID-19 period,

Table 4: Prescribed drugs to treat patients with nosocomial infections in the non-COVID-19 and COVID-19 periods.

Drug	Non-COVID-19 period n (%)	COVID-19 period n (%)	Total n (%)
Amoxicillin	0 (0.0%)	1 (9.1%)	1 (2.4%)
Amoxicillin/clavulanic acid	4 (12.9%)	2 (18.2%)	6 (14.3%)
Ceftazidime	1 (3.2%)	1 (9.1%)	2 (4.8%)
Ceftriaxone	4 (12.9%)	1 (9.1%)	5 (11.9%)
Cefuroxime	3 (9.7%)	1 (9.1%)	4 (9.5%)
Fluconazole	1 (3.2%)	0 (0.0%)	1 (2.4%)
Fosfomycin	3 (9.7%)	1 (9.1%)	4 (9.5%)
Levofloxacin	1 (3.2%)	0 (0.0%)	1 (2.4%)
Linezolid	2 (6.5%)	0 (0.0%)	2 (4.8%)
Meropenem	2 (6.5%)	0 (0.0%)	2 (4.8%)
Nitrofurantoin	1 (3.2%)	0 (0.0%)	1 (2.4%)
Piperacillin-tazobactam	7 (22.6%)	3 (27.3%)	10 (23.8%)
Trimethoprim-sulfamethoxazole	2 (6.5%)	1 (9.1%)	3 (7.1%)
Total	31 (100%)	11 (100%)	42 (100%)

with one nosocomial infection evicted by each nine patients approached with such preventive measures, and a risk reduction of 1.5 times. These data confirm and underly the major importance of systematic implementation of preventive measures. Patients with occurrence of NI have prolonged length of stay in comparison with those free of such event. Also, such group exhibited a greater number of deaths during hospital stay, even though this difference had no significant statistical value.

Even though we report a statistically significant reduction in the global prevalence of NI, when analysing individual types of NI, we only validate a statistically significant reduction in respiratory tract infections (6.3% to 1%). We postulate that generalized professional mask usage may play a role in reducing the frequency of respiratory tract infections. Also, considering that all admitted patients wore masks during hospital stay, we claim that a reduction in patient-to-patient transmission may also be responsible for such reduction. On another hand, surface cleaning leads to a safer environment that can play a role in reduction oropharynx colonization by nosocomial agents that eventually would lead to infection.

When specifically analyzing nosocomial urinary tract infections (UTI), another factor comes into discussion. Our data show a non-significant ($p = 0.106$) reduction from 15 to 8 cases (7.8% to 4.0%). Looking at both COVID-19 and non-COVID-19 periods, we report use of urinary catheter in 33.1% ($n = 130$) patients. Also, in both periods, there were 23 cases of UTI, of which 14 occurred in patients who underwent urinary catheterization. This difference in frequency demonstrated a statistically significant value, with a marked association ($OR = 3.4$) between the presence of urinary catheter and the development of UTI. The urinary catheter bias can justify the absence of statistically significant reduction in the frequency of UTI as it concurs for and increases UTI occurrence. Despite such limitation, the confirmation of the well-known association between urinary catheterization and UTI development underlies the importance of strict criteria when using such device and proactive daily evaluation of its maintenance to further reduce UTI in Internal Medicine and other wards.¹³ IPC protocols also focus on management of external devices, including urinary catheters. Although our rate of urinary catheter use might be considered high (33.1%), in our hospital there is a commission for the control of catheter associated UTI that focus on assuring that its use follows strict indications and that it is removed as soon as possible.

Although we cannot statistically corroborate the reduction in the remaining NI, probably due to its low number, every type of infection showed at least no increase in frequency in the COVID-19 period.

We report a statistically significant reduction in antibiotic use in the COVID-19 period consistent with the reduction in the frequency of NI. Such antibiotic usage reduction adds value to the global scenario, being a useful tool to reducing

bacterial selection and, consequently, antibiotic resistance and improving personal and global outcomes.¹⁴ We also found a statistically significant reduction in the incidence of NI by MDR agents, from 29.0% in the non-COVID-19 period to 9.1% in the COVID-19 period, with one MDR microorganism infection prevented by each 24 patients approached with those preventive measures. Even though the MDR profile of an institution reflects global longitudinal policies, we postulate that the observed reduction in MDR nosocomial infections comes as a result of IPC protocols implemented and it is an added value in terms of patients' outcome, broad-spectrum antibiotic sparing, and global hospital costs.

Although we report a reduction in the number of NI in the COVID-19 period, our data show a higher frequency of deaths in such period, in line with previous published data.^{15,16} This significant increase of mortality rate (7.8% to 15.9%) is not associated with the occurrence of NI, as in both periods there was no statistically significant relationship between the two variables. During the pandemic, there was a subjective feeling that patients may be experiencing fear and anxiety of looking for hospital care, fact we postulate to be responsible for a delay in timing of admission and consequent worse admission status, aggravated associated prognosis, and even death. Another fact that may be responsible for such increase of this adverse outcome may be the forced reduction in programmed activity of the outpatient clinics, which are moments of major importance in the management of patients with chronic conditions and early detection of decompensation. We postulate that the significant increase in central venous catheter usage also occurred because of worse clinical baseline status of COVID-19 period patients.

LIMITATIONS

We were able to identify some limitations in our work. Being an unicenter study, our results may not be applicable to other hospital realities. Besides, being an observational study and because the collected and analysed data were obtained from electronic medical records there is a possibility that information is lacking. Finally, there is no implemented systematic screening for MDR such as carbapenamase-producing enterobacteriaceae or methicillin-resistant *Staphylococcus aureus*. Such implementation could strengthen our data interpretation and help reducing NI.

Conclusion

We confirm a reduction in the occurrence of NI after implementation of systematic infection control protocols to prevent SARS-CoV-2 transmission. Such reduction may have long term benefits in either economic factors, clinical outcome, or social impact of hospitalization. Further investigation to validate our data and cost-benefit analysis should be performed in order to clarify if universal implementation of our infection prevention and control measures could bring up value in the

management of all patients. Such questions could be answered in a prospective multicenter study.

ACKNOWLEDGMENTS

We would like to thank Fátima Lampreia MD for her support in this study. ■

Declaração de Contribuição / Contributorship Statement:

B. M. Laura, M. S. Gonçalo - Redação do manuscrito, Revisão bibliográfica, Colheita de dados.

I. Marta, M. V. Marta, M. Carolina, R. Inês, S. Leonor, F. M. Carmo - Revisão bibliográfica, Colheita de dados.

Responsabilidades Éticas

Conflitos de Interesse: Os autores declaram a inexistência de conflitos de interesse na realização do presente trabalho.

Fontes de Financiamento: Não existiram fontes externas de financiamento para a realização deste artigo.

Confidencialidade dos Dados: Os autores declaram ter seguido os protocolos da sua instituição acerca da publicação dos dados de doentes.

Proteção de Pessoas e Animais: Os autores declaram que os procedimentos seguidos estavam de acordo com os regulamentos estabelecidos pelos responsáveis da Comissão de Investigação Clínica e Ética e de acordo com a Declaração de Helsínquia da Associação Médica Mundial.

Proveniência e Revisão por Pares: Não comissionado; revisão externa por pares.

Ethical Disclosures

Conflicts of interest: The authors have no conflicts of interest to declare.

Financing Support: This work has not received any contribution, grant or scholarship

Confidentiality of Data: The authors declare that they have followed the protocols of their work center on the publication of data from patients.

Protection of Human and Animal Subjects: The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Provenance and Peer Review: Not commissioned; externally peer reviewed.

© Autor (es) (ou seu (s) empregador (es)) e Revista SPMI 2022. Reutilização permitida de acordo com CC BY-NC. Nenhuma reutilização comercial.

© Author(s) (or their employer(s)) and SPMI Journal 2022. Re-use permitted under CC BY-NC. No commercial re-use.

Correspondence / Correspondência:

Laura Moreira – 58.laura@gmail.com

Department of Internal Medicine 1.4, Centro Hospitalar Universitário de Lisboa Central,

Hospital de São José, Lisbon, Portugal;

R. José António Serrano, 1150-199 Lisboa

Received / Recebido: 18/10/2021

Accepted / Aceite: 16/12/2021

Publicado / Published: 22/03/2022

REFERENCES

- Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control*. 2008;36:309–32.
- Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducomble T, et al. Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. *PLoS Med*. 2016;13:e1002150. doi: 10.1371/journal.pmed.1002150.
- WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health [Internet]. [cited 2020 Oct 10]. Available from: <https://www.who.int/mediacentre/news/releases/2014/amr-report/en/>
- Tchouaket EN, Beogo I, Sia D, Kilpatrick K, Séguin C, Baillot A, et al. Protocol for a systematic review of economic analyses of nosocomial infection prevention and control interventions in OECD hospitals. *BMJ Open*. 2020;10:e037765. doi: 10.1136/bmjopen-2020-037765.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382:727–33. doi: 10.1056/NEJMoa2001017.
- Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. *Eur J Clin Microbiol Infect Dis*. 2020;39:1011–9. doi: 10.1007/s10096-020-03874-z.
- Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). *J Microbiol Biotechnol*. 2020;30:313–24. doi: 10.4014/jmb.2003.03011.
- Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. *N Engl J Med*. 2020;382:2158–60.
- Doshi RK, Patel G, Mackay R, Wallach F. Healthcare-associated Infections: epidemiology, prevention, and therapy. *Mt Sinai J Med*. 2009;76:84–94. doi: 10.1002/msj.20070.
- S Harbarth, C Ruef, P Francioli, P, Widmer A, Pittet D. Nosocomial infections in Swiss university hospitals: a multi-centre survey and review of the published experience. *Swiss-Noso Network. Schweiz Med Wochenschr*. 1999;129:1521–8.
- Nicastrì E, Petrosillo N, Martini L, Larosa M, Gesu GP, Ippolito G; INF-NOS Study Group. Prevalence of nosocomial infections in 15 Italian hospitals: first point prevalence study for the INF-NOS project. *Infection*. 2003;31 Suppl 2:10–5.
- Eriksen HM, Iversen BG, Aavitsland P. Prevalence of nosocomial infections in hospitals in Norway, 2002 and 2003. *J Hosp Infect*. 2005;60:40–5.
- Shuman EK, Chenoweth CE. Urinary Catheter-Associated Infections. *Infect Dis Clin N Am*. 2018;32:885–97.
- Karam G, Chastre J, Wilcox MH, Vincent JL. Antibiotic strategies in the era of multidrug resistance. *Crit Care*. 2016;20:136. doi: 10.1186/s13054-016-1320-7
- Vestergaard LS, Nielsen J, Richter L, Schmid D, Bustos N, Braeye T, et al; ECDC Public Health Emergency Team for COVID-19, Krause TG, Mølbak K. Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020. *Euro Surveill*. 2020;25:2001214. doi: 10.2807/1560-7917.ES.2020.25.26.2001214.
- Nogueira PJ, De Araújo Nobre M, Nicola PJ, Furtado C, Vaz Carneiro A. Excess Mortality Estimation During the COVID-19 Pandemic: Preliminary Data from Portugal. *Acta Med Port*. 2020;33:376–83. doi: 10.20344/amp.13928.